This could either be the most incredible fake scientific news or the most unlistened scientific conclusion ever. 2007, I checked and apparently it is on PubMed ...
Updated @Uroweb Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
#VisualAbstract@AlbigesL@Uromigos@MichaelStaehler
https://t.co/ZAmSqFE411
Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL)
@prokarurol @MiekeVHR @GSTTnhs#VisualAbstract
https://t.co/RaHohLXZPy
#CARMENA french trial is released today! GAME CHANGER Breaking News no more CYTOREDUCTIVE NEPHRECTOMY in metastatic #kidneycancer ! 450 pts: Sunitib alone was not inferior to nephrectomy + sunitinib for OS! Stop surgery in these patients #eauguidelines#ASCO18@ASCO@AFUrologie
Impressive pCR (~40%) & tolerability with neoadjuvant atezo (Powles et al) or pembro @AndreaNecchi et al in MIBC, exciting data: PDL1, CD8 T cells, GEP, TMB, DDR: need for COMPOSITE biomarker but how to align biomarkers across trials?? @apolo_andrea@ERPlimackMD@OncoBellmunt
Our innovative single-port platform: da Vinci SP Surgical System received new @US_FDA clearance for urological surgical procedures. Learn more about the latest in our integrated product family: https://t.co/njtV9vfkye #urology
Multiparametric Magnetic Resonance Imaging for #BladderCancer : Development of VI-RADS (Vesical Imaging-Reporting And Data System) https://t.co/ugdYbnAt0T
The indeterminate lesions in prostate MRI (a literature review) - including smart management pathway proposal by @JGomezRivas.
What to do with the PI-RADS 3 lesion?
https://t.co/Wr5kyrJkoo
Majority of patients without preference for male vs. female urologists;
more patients w/ incontinence prefer same gender
https://t.co/UXEuTzDgJZ
@DartmouthUro@EliasHyams